

# New Paradigm - R&D Treaty

# Basic obligations


1. Every country is required to support medical R&D
2. The obligation would be a fraction of GDP
3. The fraction would depend upon the level of development
4. Countries would have flexibility in terms of how the R&D was financed and managed
5. Purchases of patented medicines, public sector research, prize funds, etc, would be allowed, to the degree that they stimulate R&D

Investments in some certain projects that are important earn credits. These credits are tradable between countries

- Priority research/neglected diseases
- Open research
- Exceptionally useful projects
- Preservation and dissemination of traditional medical knowledge
- Technology transfer, capacity building

*(Subject to some caps)*

# Treaty mechanisms overview



# Treaty Supporters

James Love, Director, CPTech, Washington, DC, USA \* Tim Hubbard, Head of Human Genome Research, Wellcome Trust Sanger Institute, Cambridge, UK. Martin Khor, Third World Network, Malaysia \* Sir John Sulston, Winner of 2002 Nobel Prize for Physiology or Medicine, Former Director of the Wellcome Trust Sanger Institute, Cambridge, UK \* Dominique Stoppa-Lyonnet, Head of the Genetics Department of the Medical Division of the Institut Curie, Paris, France \* Dr. Massimo Bara, Vice President, International Federation of the Red Cross \* Ellen 't Hoen, Director of Policy Advocacy and Research, Access to Essential Medicines Campaign, Médecins sans Frontières \* Oxfam International \* Spring Gombé, Health Action International (HAI) \* Anna Fielder, Director, Consumers International, Office for Developed and Transition Economies, London, USA \* Bernard Sanders, Member, United States House of Representatives, USA \* Ian Gibson MP, Chair, House of Commons Select Committee on Science and Technology, UK \* Alain Claeys Député de la Vienne, France \* Claude Hurlet, Ancien sénateur de la Meurthe-et-Moselle, France \* David Hammerstein, Member of European Parliament, Spain \* Jean-Luc Bennahmias, Member of European Parliament, France \* Daniel Cohn-Berdit, Member of the European Parliament \* Luisa Morgantini, Member of the European Parliament, Italy \* Monica Frassonin, Member of the European Parliament, Co-President of the Green/Efa Group, Italy \* Glenys Kinnock, Member of the European Parliament, Co-President of the ACPEU Joint Parliamentary Assembly, UK \* Vittorio Agnoletto, Member of the European Parliament, former president of LILA - Italian League for the fight against AIDS, group GUE/NGL, Italy \* Dr. Dorrette Corbey, Member of European Parliament, The Netherlands \* Dr. Rodrigo Salinas, Director, Instituto de Salud Pública de Chile, Santiago de Chile \* Cristina de Albuquerque Possas, Head of Research and Technological Development Unit National STD/Aids Program, Ministry of Health, Brazil \* Dr. Benjamin Gibert, Institute for Pharmaceutical Technology, Fundação Oswaldo Cruz, Ministry of Health, Brazil \*

William W. Fisher III, Hale and Dorr Professor of Intellectual Property Law, Harvard Law School, USA \* Peter Suber, Open Access Project Director, Public Knowledge, Research Professor of Philosophy, Earlham College, US \* HeeSeob Nam, Intellectual Property Left, Patent Attorney, Korea \* Dr. Christian Wagner, BUKO Pharma-Kampagne, Bielefeld, German \* Ruth Mayne, Oxford Brookes University, UK \* James Boyle, William Neal Reynolds Professor of Law, Duke University, USA \* Peter Drahos, Professor and Head of Program, Regulatory Institutions Network, Research School of Social Sciences, Canberra, Australia \* Jonathan Berger, AIDS Law Project, South Africa \* Nathan Geffen, Treatment Access Campaign, South Africa \* Lawrence Lessig, Professor of Law at Stanford Law School, Chairman of the Creative Commons, USA \* Nicoletta Dentico, President, Global Health Watch in Rome, Italy \* Jiraporn Limpananont, Ph.D., Chair of Social Pharmacy Research Unit, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand \* Andy Gray, Senior Lecturer, Dept of Therapeutics and Medicines Management, Nelson R Mandela School of Medicine, Durban, South Africa \* Joel Lexchin MD, School of Health Policy and Management, York University, Toronto, Ontario, Canada \* Joan Rovira, Director of Research for SOIKOS (Centro de Estudios en Economia de la Salud y de la Politica Social) Barcelona, Spain \* Frederick M. Abbott, Edward Ball Eminent Scholar, Professor of International Law, Florida State University College of Law, USA \* Prof Udo Schuklenk, Chair in Ethics and Public Policy, Glasgow Caledonian University, UK \* Suntaree Vitayanatpaisan, Chairperson, Drug Study Group (DSG), Bangkok, Thailand \* Charles Medawar, Director, Social Audit Ltd, London, UK \* Dr. Shyama V. Ramani, Department of Economics, INRA (Institut National de la Recherche Agronomique) - Universite Pierre Mendes, France \* Donald Light, Professor of Comparative Health Care Systems, University of Medicine and Dentistry of New Jersey, USA \* Talha Syed, Doctoral Candidate, Harvard Law School, USA \* Dr. Alexander C. Tsai, Case Western Reserve University School of Medicine, USA \* Mei-ling Wang, Ph.D, Associate Professor of Social Sciences and Health Policy, University of the Sciences in Philadelphia, USA \* Carolyn Deere, Global Economic Governance Programme, Oxford University, UK \* Warren Kaplan, Center for International Health and Development, Boston University School of Public Health, USA \* Leonard Rodberg, Associate Professor and Chair, Urban Studies Department Queens College/CUNY, NY, USA

Terence H. Young, Chair, Drug Safety Canada, Ontario, Canada \* Madeline Boscoe, R.N, Advocacy Coordinator, Women's Health Clinic, Winnipeg, Canada \* Harriet G. Rosenberg, Ph.D., Health and Society Programme, York University, Toronto, Canada \* Richard J. Brown, MD, Board, Physicians for a National Health Program, NY Metro Chapter, USA \* Dr. Andrew Herxheimer, Emeritus Fellow, Cochrane Centre, UK \* Dr. Jillian Clare Cohen, Assistant Professor, Leslie Dan Faculty of Pharmacy, University of Toronto, Canada \* Richard Stallman, Founder, Free Software Foundation, USA \* Elia Abi-Jaoude, Psychiatry Resident, University of Toronto, Canada \* Institute for Agriculture and Trade Policy, USA \* Barbara Mintzes, Centre for Health Services & Policy Research, University of British Columbia, Canada \* Alan Cassels, Drug policy researcher, School of Health Information Science, University of Victoria, Victoria, BC Canada \* John Howkins, Director, IP Charter, London, UK \* David Dudley, Attorney, USA \* Kevin Outterson, Associate Professor of Law, West Virginia University, USA \* Professor Anil K. Gupta, Kasturbhai Lalbhai Chair in Entrepreneurship, Indian Institute of Management, India \* Dr. Ikrame MOUCHARIK, membre d'ATTAC Maroc, Morocco \* Gazanfer Aksakoglu, Professor and Head, Department of Community Medicine, Dokuz Eylul University, Izmir, Turkey \* Robert Weissman, Director, Essential Action, Washington, DC, USA \* David M. Olson, M.D., Medical Advisor, Medecins Sans Frontieres-USA \* Michael Geist, Canada Research Chair in Internet and E-commerce Law, University of Ottawa, Canada \* Aidan Hollis, Associate Professor, Department of Economics, University of Calgary, Canada \* Bob Huff, Editor, GMHC Treatment Issues, New York, USA \* George M. Carter, Director, Foundation for Integrated AIDS Research (FIAR), Brooklyn, NY, USA \* Dr. B. Ekbal, National Convenor Peoples Health Movement (Jan Swasthaya Abhiyan), India \* Dr. Valeria Frighi, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, UK \* Pierre Druilhe, Head BioMedical Parasitology Unit, Pasteur Institute, Paris, France \* Dr. Anthony Bryceson, Emeritus Professor of Tropical Medicine, London School of Hygiene and Tropical Medicine, London \* Prof. Dr. F. Cankat Tulunay, President of Turkish Clinical Pharmacological Society, Medical School of Ankara University, Department of Clinical Pharmacology, Turkey \* Ga'Il e Krikorian, France \* Robin Gross, Executive Director, IP Justice, San Francisco, USA \* Nathan Ford, Head of Medical Unit, M'decin s sans Fronti, res -UK \* David Scondras, Search for a Cure, Cambridge, USA \* Beth Burrows, Director, Edmonds Institute, USA \* Joan-Ramon Laporte, Professor of Clinical Pharmacology, Universitat Autònoma de Barcelona, Institut, Catala de la Salut, Barcelona, Spain \* Professor Brook K. Baker, Northeastern University School of Law, Health Global Access Project, USA



David Henry, Professor of Clinical Pharmacology, Consultant Physician, University of Newcastle, New South Wales, Australia \* Paul Davis, Health GAP (Global Access Project), USA \* Carles Roersch, Director, Instituto de Medicina Dominicana, Santo Domingo, Dominican Republic \* Pierre Chirac, Access to Essential Medicines Campaign, M<sup>é</sup>decins sans Frontières, Paris, France \* Mr. Nikolaos Tsemperlidis, President, and Mrs. Evangelia Kekeleki, General Secretary, KEPKA-Consumers Protection Centre, Thessaloniki, Greece \* Pedro Roffe, Senior Fellow ICTSD, Director, UNCTAD-ICTSD Project on Intellectual Property and Sustainable Development, International Centre for Trade and Sustainable Development (ICTSD), Geneva, Switzerland \* Dr. Angelo Stefanini, Department of Medicine and Public Health, University of Bologna, Italy, Osservatorio Italiano sulla salute Globale - OISG, Italy \* Darius Cuplinskas, Director, Information Program, Open Society Institute \* Hervé Le Crosnier, Université de Caen (France) et Vecam, France \* Valérie Peugeot, Vecam, France \* Amy Nunn, Harvard School of Public Health, Department of Population and International Health, Harvard University, USA \* Carlos Passarelli, Project Advisor, Brazilian Interdisciplinary AIDS Association (ABIA), Coordinator of the Work Group on Intellectual Property of the Brazilian Network for the Integration of the Peoples (REBRIP), Brazil \* Claude Henry, Professor, Ecole Polytechnique, Paris, France \* Dorothée Benoit Browaeys et Jean Jacques Perrier, Science Journalists, Editors, electronic Magazine Vivantinfo.com, Paris, France \* Dr. Patrice Trouiller, Neglected Diseases Group, Antananarivo, Madagascar \* Peter Eckersley, Intellectual Property Research Institute of Australia, University of Melbourne, Australia \* Shyam Sundar, Banaras Hindu University, India \* Maristela Basso, International Trade Law and Development Institute, São Paulo, Brazil \* Dr. K Balasubramaniam, Co-ordinator, Health Action International Asia - Pacific, Sri Lanka \* Oscar Bruña-Romero, Professor at the Department of Microbiology/Federal University of Minas Gerais and Scientist at the Fundação Oswaldo Cruz (FIOCRUZ), Belo Horizonte, Brazil \* Ana Rabello, Centro de Pesquisas René Rachou/Fundação Oswaldo Cruz (FIOCRUZ), Belo Horizonte, Brasil \* H. David Banta, MD, MPH, Professor Emeritus of Health Technology Assessment, University of Limburg, Maastricht, the Netherlands, and Mount Sinai School of Medicine, New York City, Staff member of the World Health Organization (retired) \* Prof Tariq Iqbal Bhutta, Lahore, Pakistan \* Staffan Svensson, MD, Dept of Clinical Pharmacology, Sahlgren's Univ Hospital, Gothenburg, Sweden \*

Wija J. Oortwijn, PhD, Senior Analyst, RAND Europe , The Netherlands \* Ali Qadir, TheNetwork for Consumer Protection, Pakistan \* Dr. Ken Harvey, School of Public Health, La Trobe University, Australia \* Rufus Pollock, Director, Open Knowledge Foundation \* Anwar Fazal, Chairperson Emeritus, World Alliance for Breastfeeding Action \* Professor Martin Bobrow, FRS, University of Cambridge, Department of Medical Genetics, UK \* Karen Seabrooke, Women's Health Interaction, Canada \* Marie de Cenival, SIDACTION, Paris, France \* Mauro Guarinieri, Chair, Board of Directors, European AIDS Treatment Group, Brussels, Belgium \* Wim Vandevelde, President, GAT - Grupo Portugues de Activistas sobre Tratamentos de VIH/SIDA, Portugal \* Scott Lee, Woodrow Wilson School of Public and International Affairs, Princeton University, USA \* Muntaser Eltayeb Ibrahim, Institute of Endemic Diseases, University of Khartoum, Sudan \* Peter Lockley, Open Knowledge Foundation, UK \* Margaret Chon, Professor, Seattle University School of Law, USA \* Tenu Avafia, Researcher, Trade Law Centre for Southern Africa, Stellenbosch, South Africa \* Professor Renato Cutrera, Chief, Bronchopneumology Department, Bambin Gesù Pediatric Hospital, Rome, Italy \* Rhoda Karpatkin, President Emeritus, Consumers Union, USA \* Emanuele Nicastrì, National Institute for Infectious Diseases, Rome, Italy \* Jacques Juillard, President, Association Mieux Prescrire, publisher of la revue Prescrire and Prescrire International, France \* Bruno Toussaint, Editor-in-chief, la revue Prescrire, France \* Christophe Kopp, Managing Editor, Prescrire International, France \* Adriano Cattaneo, Unit for Health Services Research and International Health, IRCCS Burlo Garofolo, Trieste, Italy \* Philippa Saunders, Essential Drugs Project, UK \* Fabrizio Tediosi, Swiss Tropical Institute, Swiss Centre for International Health, Basel, Switzerland \* Dr. Francis DELPEYROUX, INSERM (French National Institute of Health and Medical Research), France \* Dr. Sunil Deepak, Director, Medical Support Department, AIFO - Bologna, Italy \* Joana Ramos, Cancer Resources & Advocacy, Seattle, USA \* Julien Reinhard, The Berne Declaration, Switzerland \* Sean Flynn, Esq., Director, Institute on Law and Development, Washington, DC, USA \* Samantha Power, Lecture in Public Policy, Carr Center for Human Rights Policy, Harvard University, USA \* Els Torreele, Drugs for Neglected Diseases initiative (DNDi), Switzerland \* Gert Matthijs, Head of Molecular Diagnostics Laboratory and Professor of Human Genetics, University of Leuven, Belgium \* Steve Cowper, Steve Cowper & Associates, former Governor of Alaska (1986-1990), Austin, Texas, USA \* Dr. John Erickson, Director, Institute for Global Therapeutics, Gaithersburg, MD, USA \* Mr. B.K. Keayla, Secretary General & Managing Trustee, Centre for Study of Global Trade, System and Development, New Delhi, India

Madeleine R. Valera, MD, MScCHHM, Vice President for Quality Assurance Research and Policy Development Group, Philippine Health Insurance Corporation, Philippines \* Ambrocio C. Ramos, Quality Assurance Research and Policy Development Group, Philippine Health Insurance Corporation, Philippines \* Ornella Abollino, Faculty of Pharmacy, University of Torino, Italy \* Pierre-Henri Gouyon, Directeur du laboratoire UPS-CNRS d'Ecologie, Systématique et Evolution, ainsi que professeur à l'Université Paris-Sud, à l'Agro et à l'École Polytechnique, France \* Philippe Aigrain, Transversales Science-Culture, France \* Professor Sir David Weatherall FRS, UK \* Gøran Tomson, Professor International Health Systems Research, IHCAR Div International Health, Dept Public Health Sciences and Director of Doctoral Programme, Medical Management Centre, Karolinska Institutet, Stockholm, Sweden \* Ramadhan R. Madabida, Chief Executive Officer, Tanzania Pharmaceutical Industries Ltd. Dar es Salaam, Tanzania \* Dr. Laura Celesti-Gradow, Department of Plant Biology, University of Rome "La Sapienza," Italy \* Dr. David McCoy, Specialist Public Health Registrar, North East London Health Protection Unit, UK \* Dr. Michael C. Latham, Graduate School Professor, Division of Nutritional Sciences, Cornell University, New York, USA \* Virginia Thorley, Lactation Consultant and Historian, Brisbane, Queensland, Australia \* S. Srinivasan, Managing Trustee, Low Cost Standard Therapeutics (LOCOST), Baroda, India \* Carlos Cajas, Agrocentro, Guatemala \* Derek Yach, Head of the Global Health Division, Department of Epidemiology and Public Health, Yale University, USA \* Professor Gordon Dougan, Principal Research Scientist, Member of the Board of Management, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK

EB117.R13

[Global framework on] essential  
health and development

In January, WHO EB forwarded  
resolution to WHA for debate in May  
2006

# For more information

CPTech

<http://www.cptech.org>

[james.love@cptech.org](mailto:james.love@cptech.org)